Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Prevention and Management of Injection Site Reactions in Type 2 Inflammation-Targeted Biologic Therapies for Atopic Dermatitis: A Practical Clinical Algorithm for Contemporary Dermatologic Practice.","authors":"Andrew Baker, Leigh Ann Pansch","doi":"","DOIUrl":"","url":null,"abstract":"<p><p><b>INTRODUCTION:</b> Biologic therapies targeting the type 2 inflammatory pathway have transformed the management of moderate-to-severe atopic dermatitis (AD). Injection site reactions (ISRs) are the most common localized adverse events associated with these agents and might influence treatment persistence. <b>OBJECTIVE:</b> To present a practical, evidence-informed clinical framework for the prevention and management of ISRs associated with type 2 biologic therapies used in the treatment of AD. <b>METHODS:</b> A narrative review of ISR incidence reported in pivotal phase 3 trials was integrated with real-world observational evidence and contemporary prescribing trends within advanced practice clinician (APC)-integrated dermatologic practice. <b>RESULTS:</b> Across pivotal trials of type 2 pathway biologics, ISR incidence has ranged from approximately 4% to 19%, depending on mechanism of action and comparator arm. Interleukin (IL)-4/IL-13 pathway inhibition has demonstrated ISR rates of approximately 10% to 18%, compared with 6% to 10% in placebo arms. Selective IL-13 inhibitors have shown ISR rates ranging from 4% to 14%, while IL-31 receptor blockade trials have reported localized reactions in approximately 8% to 15% of participants. Real-world observational and meta-analytic data confirm that most ISRs are mild to moderate in severity and rarely lead to treatment discontinuation, with discontinuation rates generally reported between 1% and 2%. <b>DISCUSSION:</b> Although numerically common, ISRs are typically benign, self-limited, and manageable with appropriate counseling and supportive care. Variability in reported incidence likely reflects differences in molecular structure, formulation characteristics, delivery devices, and trial methodology rather than meaningful differences in systemic safety. Structured anticipatory guidance and standardized management pathways might reduce anxiety-driven discontinuation and improve treatment persistence. <b>CONCLUSION:</b> Proactive counseling, optimization of injection technique, and symptom-directed management strategies can reduce morbidity associated with ISRs and support long-term adherence in dermatologist-directed, APC-integrated practice models.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7-8 Suppl 1","pages":"S10-S12"},"PeriodicalIF":0.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Evolution of Topical Retinoids in Dermatology: A Cornerstone of Acne Management (1971-2025).","authors":"Linda Stein Gold, Hilary Baldwin, James Q Del Rosso, Seemal Desai, Julie C Harper, Firas G Hougeir, Camille Howard-Verovic, Leon Kircik, Monica K Li, Neera R Nathan, Naiem T Issa","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Topical retinoids have been a cornerstone in the management of acne vulgaris for over 5 decades, and they remain important even as treatment paradigms evolve. There is an ongoing need to understand the history and context of current retinoid use to support future innovations and improvements in the care of patients with acne.</p><p><strong>Methods: </strong>Peer-reviewed literature was searched to identify articles related to topical retinoids, including their development, receptor selectivity, mechanisms of action, efficacy, tolerability, and role in the treatment of acne and management of acne sequelae.</p><p><strong>Results: </strong>Molecular design for stability and receptor-specific activity distinguishes the retinoid generations. Increased selectivity for retinoic acid receptor γ (RARγ) has changed the profile of modulated genes, with many of the altered genes having known roles with implications in the pathogenesis of acne and acne sequelae. Finally, the potential of retinoids to manage acne sequelae, such as atrophic scarring and acne-induced hyperpigmentation, has been demonstrated in clinical trials.</p><p><strong>Limitations: </strong>Most available studies are heterogeneous in design, with few large-scale trials directly comparing newer selective RARγ agonists with older agents. Moreover, long-term safety data beyond 1 year are limited, and real-world adherence metrics are underreported. Finally, formulation variability across studies complicates direct efficacy and tolerability comparisons.</p><p><strong>Conclusion: </strong>Advancements in the selectivity of retinoids, adjunctive skincare, and patient education have reduced adverse effects of topical retinoids and improved adherence. A thorough understanding of retinoid biology and pharmacology is essential for dermatologists to optimize patient outcomes and maximize the therapeutic potential of this important drug class.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"54-66"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the Path Forward.","authors":"Albert E Zhou, Christian Gronbeck, Jenny J Kim, Siegrid Yu, Hao Feng, Daniel M Klufas","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Mohs micrographic surgery (MMS) unites staged extirpation, comprehensive intraoperative histopathologic assessment, and immediate reconstruction to deliver durable local control with tissue conservation in anatomically critical sites. Contemporary practice, however, is shaped by intersecting forces: stewardship of indications, reimbursement trends, vertical consolidation, expanding use of intraoperative immunohistochemistry (IHC), and the emergence of complementary modalities (superficial radiation therapy; hedgehog and programmed cell death-1 [PD-1] inhibitors) alongside digital tools (teledermatology, artificial intelligence [AI], optical coherence tomography [OCT], reflectance confocal microscopy [RCM]).</p><p><strong>Objective: </strong>To provide a narrative synthesis that clarifies where MMS adds the greatest value, delineates the appropriate roles of competing and complementary treatments, and outlines pragmatic steps (clinical, economic, and educational) to preserve high-quality, margin-controlled cutaneous oncology.</p><p><strong>Methods: </strong>We conducted a structured narrative review of MEDLINE and Embase (January 2000-December 2025) using controlled vocabulary and keywords for MMS; basal cell and cutaneous squamous cell carcinoma; melanoma in situ; radiation therapy; systemic therapy (hedgehog/PD-1); IHC; teledermatology/AI; and optical imaging (OCT/RCM). Eligible studies included randomized trials, prospective cohorts, comparative observational studies, systematic reviews/meta-analyses, and cost or reimbursement analyses reporting local control/recurrence, complications, episode-level cost, or implementation outcomes.</p><p><strong>Conclusion: </strong>MMS provides superior or noninferior oncologic control with tissue preservation, same-day repair, and favorable safety in ambulatory settings. Appropriate use criteria should be framed as clinical stewardship, while superficial radiation and systemic therapies are best positioned as complements to MMS when surgery is infeasible or as neoadjuvant/adjuvant strategies. Sustaining the value of MMS will require explicit documentation of surgeon work and practice expense, standardized outcomes and patient-reported measures, equitable workforce strategies, and measured adoption of validated technologies such as OCT/RCM and AI. Payers and policymakers should recognize and preserve the true clinical and economic contribution of MMS.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"73-78"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Topical and Oral Creatine on Skin Firmness and Resilience: A Review.","authors":"Nicole Werpachowski, Lyudmyla Susla, Milana Stein, Karan Lal","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Skin quality declines with intrinsic aging, environmental damage, and oxidative stress. Loss of skin firmness, a hallmark of aging, results from collagen degradation and fibroblast dysfunction, weakening the extracellular matrix (ECM). This leads to increased laxity and wrinkle formation, known as dermatoporosis. Creatine, a naturally occurring compound essential for cellular energy metabolism, has emerged as a potential agent for improving skin firmness.</p><p><strong>Objective: </strong>To examine the effects of topical and oral creatine supplementation on skin firmness, focusing on cellular mechanisms and clinical evidence.</p><p><strong>Methods: </strong>A literature search was conducted in March 2025 using PubMed, Google, and Google Scholar. Studies investigating creatine's effects on the integumentary system were reviewed and summarized.</p><p><strong>Results: </strong>While clinical studies on creatine's effects on skin firmness are limited, in vivo and in vitro research suggest that topical creatine enhances skin elasticity and firmness while providing photoprotective benefits. These effects appear to be achieved with minimal risk when used at recommended doses. Although no direct studies on oral creatine's impact on skin firmness were found, its systemic absorption and demonstrated benefits in other physiologic processes suggest a potential role in skin health.</p><p><strong>Limitations: </strong>While preliminary findings suggest dermatologic benefits of creatine, research is limited by a lack of studies isolating creatine's effects, scarce in vivo data, and insufficient long-term safety assessments.</p><p><strong>Conclusion: </strong>Emerging evidence suggests that both oral and topical creatine may enhance skin firmness by supporting collagen metabolism and fibroblast function. However, further research is needed to establish clinical efficacy.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"67-72"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating Atopic Dermatitis Prevention With Omega-3 Supplementation in Different Ethnic Populations.","authors":"Amjad El Othmani, Hailey Olds, Hussein Bazzi, Lina Shalaby, Meena Moossavi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting approximately 5% of adults and 13% of children worldwide. Individuals with skin of color (SOC) are disproportionately affected and often experience more severe disease manifestations, including pigmentary changes and lichenification. Despite these disparities, SOC populations remain underrepresented in AD research, limiting the development of targeted prevention strategies. Emerging evidence suggests that omega-3 polyunsaturated fatty acids may play a protective role in AD through anti-inflammatory effects and support of the epidermal lipid barrier. However, the potential benefits of omega-3 supplementation in SOC populations have not been specifically examined. Global studies demonstrate significant geographic variation in omega-3 blood levels, with lower levels observed in many regions that include large SOC populations, suggesting that dietary differences may contribute to inflammatory disease risk. In addition, genetic variation in fatty acid desaturase genes influences endogenous omega-3 metabolism and may vary across ethnic groups, potentially affecting susceptibility to AD and responses to supplementation. Together, these dietary and genetic factors highlight the importance of evaluating omega-3 fatty acids as a potential preventive strategy in SOC populations. Further research examining omega-3 intake, fatty acid metabolism, and AD outcomes in diverse populations is needed to better understand their role in disease prevention and to address existing disparities in dermatologic care.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"36-37"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunomodulatory Therapy in Patients Living With HIV and Inflammatory Dermatoses: A Comprehensive Review of Current Protocols and Emerging Evidence.","authors":"Abigail Beard, Valerie Foy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite effective antiretroviral therapy (ART), HIV infection drives progressive immune dysfunction, complicating the management of comorbid inflammatory and autoimmune dermatologic conditions such as psoriasis, atopic dermatitis, and cutaneous lupus erythematosus. These conditions often require immunomodulatory therapies, but their use in people living with HIV (PLWH) raises concerns about heightened infection risks, impacts on viral load and CD4 counts, and interactions with ART. The advent of targeted biologics, including tumor necrosis factor, interleukin (IL)-17, IL-23, and Janus kinase inhibitors, has revolutionized treatment for immune-mediated skin diseases. However, limited clinical trial data in PLWH create uncertainty about safety and efficacy. Traditional immunosuppressants such as methotrexate and cyclosporine further complicate care due to their broad immunosuppressive effects. This review synthesizes current clinical protocols, recent guideline updates, and emerging evidence on the safety and efficacy of immunomodulatory therapies in PLWH with dermatologic conditions. By providing a concise, evidence-based framework, we aim to guide dermatologists and infectious disease specialists in optimizing treatment decisions to improve dermatologic and systemic health outcomes in this complex patient population.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"14-24"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Safety and Tolerability of a Physician-Formulated Hair Growth Supplement: A Retrospective Review of 508 Patients.","authors":"Emily Kavanaugh, Alina Galaria, Aamir N Hussain, Adel Haque","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term safety and tolerability of a physician-formulated hair growth supplement developed by a board-certified dermatologist and board-certified plastic surgeon, with particular attention to liver function testing.</p><p><strong>Methods: </strong>A retrospective chart review was conducted across four dermatology practices. The study included 508 patients who took the supplement for at least 12 weeks between July 2020 and December 2024. Duration of use ranged from 12 to 255 weeks. Eligible patients were required to have at least 2 in-person evaluations by a board-certified dermatologist. Patients were excluded if they were pregnant, concurrently taking other hair loss supplements, or had significant pre-existing medical conditions that could confound safety evaluation. Data collected included patient demographics, clinical history, physical examination documentation, and liver function test results, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, and gamma-glutamyl transferase.</p><p><strong>Results: </strong>A total of 508 patient charts met inclusion criteria. The cohort included 452 female patients (89.0%) and 56 male patients (11.0%), with an average age of 48.4 years. Participants took the supplement for an average of 34 weeks, with 92 patients taking it for more than 52 weeks and 33 patients taking it for more than 104 weeks. Overall, 48% of the total study population had documented liver function testing during the study period. All documented liver function tests remained within normal reference ranges. Among patients taking the supplement for at least 52 weeks, 80% had laboratory testing available, and all results were within normal limits. Among patients taking the supplement for more than 104 weeks, 88% had liver function testing available, and all results were within normal limits. No hepatic adverse events, clinically significant laboratory abnormalities, or liver-function-related discontinuations were reported.</p><p><strong>Limitations: </strong>Limitations include the retrospective study design, availability of laboratory data for only a subset of participants, potential selection bias, and lack of a prospective randomized control group.</p><p><strong>Conclusion: </strong>In this retrospective review of 508 patients, long-term use of the studied physician-formulated hair growth supplement was well tolerated, with no documented liver function abnormalities among patients with available laboratory data. These findings support a favorable long-term safety profile when the supplement is used as directed. Future prospective, randomized, controlled studies with standardized outcome measures are warranted to further evaluate safety and efficacy.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients-Part 2.","authors":"James Q Del Rosso, Lauren Lam, Diego Ruiz Dasilva, Joshua Burshtein, Christopher G Bunick, Lara Shqair, Andrea Murina, Katrina H Lee, Jennifer Hsiao, Tiffany Mayo, Graham Litchman, Andrew Ferrier, Michael Payette, Steve Daveluy, Victoria Farley, Vivian Shi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disorder that often starts in the second or third decade of life, induces both inflammatory and cicatricial cutaneous lesions, and frequently involves intertriginous and anogenital anatomic sites. Abscesses, nodules, and draining tunnels are reversible inflammatory lesions that cycle over time through unpredictable periods of exacerbation; cicatricial lesions are permanent and persist as fibrotic scars and nondraining tunnels, the latter reflecting the shells of prior draining tunnels. HS has a profound adverse impact on overall quality of life with many affected individuals experiencing signs and symptoms that are consistently bothersome physically, psychosocially, and medically, often interfering with several major activities of daily living and enjoyment. The reader is encouraged to review the Part 1 article of this 4-part article series, published in this journal in August 2026, which included an introductory summary of the HS disease state, overview of pathophysiology and etiology, approach to physical examination, suggested fundamental/core laboratory evaluations, and rational assessment of potential comorbidities of HS. This second article of the series covers therapeutic management principles of HS, antibiotic management of HS, adalimumab for HS, and infliximab for HS. Ultimately, the goal of this 4-part article series is to be practical, reasonably comprehensive, and clinically useful as a \"guidance tool\" to assist clinicians in managing HS. As stated in Part 1, multiple authors have separately contributed individual sections inclusive of supporting references. All authors were primarily responsible for their individual sections but also participated in the review and finalization of the complete series of articles. The order of the authors listed in the article heading reflects the order of appearance of their primary sections in the 4-part article series.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"25-35"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of Ethics and Use of Animal-Based Surgical Products in Dermatology.","authors":"Rebecca Olsen, Aarushi Gulati, Rachna Sahasrabudhe, Abdul Rahim Jaber","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Animal- and human-derived materials are commonly used in dermatologic and cosmetic products, yet their presence is often unclear to clinicians and patients.</p><p><strong>Objective: </strong>To examine ethical and informed-consent implications of these materials, particularly when they conflict with patients' religious, cultural, or personal values.</p><p><strong>Methods: </strong>A narrative literature search and product formulary audit were conducted on PubMed through February 2025, augmented by United States Food and Drug Administration summaries and manufacturer dossiers. Data extraction focused on material origin, clinical use, outcomes, adverse events, and labeling transparency.</p><p><strong>Results: </strong>Numerous dermatologic products contain animal- or human-derived components, such as rooster-comb-derived hyaluronic acid, bovine collagen grafts, shark-derived glycosaminoglycans, and human-derived materials. The source of these materials is frequently absent or inconsistently reported in labeling, limiting clinicians' ability to counsel patients effectively. Studies demonstrate that when informed and given alternatives, most patients prefer nonanimal-derived options. Advances in synthetic and bioengineered materials make such alternatives increasingly feasible.</p><p><strong>Limitations: </strong>This review is not exhaustive. Given the extent of dermatologic and cosmetic products on the market and variability in ingredient disclosure, some animal- or human-derived materials may not have been captured. Rapid product innovation and inconsistent reporting of material origins further limit comprehensive identification.</p><p><strong>Conclusion: </strong>Improved transparency regarding product origins is essential for meaningful informed consent in dermatology. Incorporating brief intake screening questions and updating consent forms to disclose material sources may enhance shared decision-making, patient trust, and ethically aligned, patient-centered care.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"42-48"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-Dimensional and Three-Dimensional High-Frequency Ultrasound of Seborrheic Keratosis.","authors":"Julian Henke, Benazir Merchant, Caroline Serafini, Devon Barrett, Myer Khan, Zakaria Khan, Jiwoong Jason Jeong, Xiaofeng Yang, Mohammed K Khan","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 9","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}